Immutep Limited
Research Immutep Limited (YP1B) on Bullrun: market cap EUR 28.00M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerYP1B
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 28.00M
- Financial periodFY2025
Valuation Snapshot
latest market cap is EUR 28.00M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | n/a | n/a | n/a | -0.04 | n/a | n/a | n/a |
| FY2024 | AUD 0 | -AUD 42.72M | -AUD 35.75M | n/a | -0.04 | AUD 161.79M | AUD 1.59M | AUD 189.52M |
| FY2023 | AUD 0 | -AUD 39.90M | -AUD 35.44M | n/a | -0.04 | AUD 123.42M | AUD 1.23M | AUD 136.47M |
| FY2022 | AUD 170.37K | -AUD 32.21M | -AUD 30.25M | n/a | -0.04 | AUD 80.00M | AUD 1.73M | AUD 94.08M |
| FY2021 | AUD 0 | -AUD 29.90M | -AUD 17.66M | n/a | -0.05 | AUD 60.13M | AUD 2.82M | AUD 73.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | EUR 28.00M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immutep Limited's market cap?
Immutep Limited's market capitalization is EUR 28.00M.
What does Immutep Limited do?
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.